Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00085553 · ClinicalTrials.gov registry record · Phase 1

Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors

A Phase 1 study of Solid Neoplasm, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 1
Development phase
29
Enrollment target
1
Study location

NCT00085553 is a Phase 1 study of Solid Neoplasm that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 29 participants, below the 941-participant average among 12 other Solid Neoplasm trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00085553, a Phase 1 study of Solid Neoplasm, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 1
Development phase
29 participants
Enrollment target
1
Study location

Study Summary

This phase I trial studies the side effects and best dose of tipifarnib and erlotinib hydrochloride in treating patients with solid tumors that have spread to other places in the body. Tipifarnib and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions Studied

Solid Neoplasm

Interventions

  • OTHER Laboratory Biomarker Analysis
  • DRUG Tipifarnib
  • DRUG Erlotinib Hydrochloride
  • OTHER Pharmacological Study

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2004-05-20
Est. Completion 2018-05-16
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00085553

The ClinicalTrials.gov registry entry for NCT00085553 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 941-participant average among 12 other Solid Neoplasm trials with a reported enrollment target (97% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT00085553 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT00085553 about?

NCT00085553 is a clinical study titled "Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors". This phase I trial studies the side effects and best dose of tipifarnib and erlotinib hydrochloride in treating patients with solid tumors that have spread to other places in the body. Tipifarnib and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed fo...

What is the current status of trial NCT00085553?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2004-05-20. Estimated completion is 2018-05-16.

What conditions does trial NCT00085553 study?

This clinical trial studies the following conditions: Solid Neoplasm.

What interventions are being tested in trial NCT00085553?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Tipifarnib (DRUG), Erlotinib Hydrochloride (DRUG), Pharmacological Study (OTHER).

Who is sponsoring clinical trial NCT00085553?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00085553 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Neoplasm

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.